FDA's Susan Alpert
This article was originally published in The Gray Sheet
Executive Summary
Former director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health will join C.R. Bard as VP-regulatory sciences, effective Oct. 1. Alpert served as ODE director for six years before transferring to FDA's Center for Food Safety and Applied Nutrition in October 1999 as director of food safety. Alpert, who holds both an MD and PhD, first joined FDA in 1987 as supervisory medical officer at the agency's Center for Drug Evaluation and Research. The title of ODE director, which has been held by CDRH Director David Feigal on an interim basis since Alpert's departure from ODE, is being passed to Bernard Statland. Appointed June 16, Statland assumes his new duties the week of July 17 (1"The Gray Sheet" June 19, p. 2)
You may also be interested in...
FDA Device Center Taps Agency Outsider Statland For Top ODE Post
FDA has appointed Bernard Statland, MD/PhD, a clinical pathologist with no previous experience at FDA, to lead its Office of Device Evaluation in the Center for Devices and Radiological Health.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.